Monday, December 29, 2014

Top 10 Tech Companies To Invest In 2015

Top 10 Tech Companies To Invest In 2015: CollabRx Inc (CLRX)

CollabRx, Inc., incorporated on September 20, 1995, is focused on developing and delivering content knowledge-based products and services that inform healthcare decision-making, with an emphasis on genomics-based precision medicine and big data analytics. The Company delivers content to users through Web-based applications and services in the cloud serving physicians and their patients in two settings: at the point-of-care in the clinic and indirectly, as a part of a genetic test report provided to an ordering physician by a diagnostic testing laboratory, (lab). The Companys Therapy Finder Web-based application serves as an initial user-interface to the underlying knowledge base. It is available free of charge on its Website. In addition, a professional version is offered to registered physicians through MedPage Today, an offering of Everyday Health, Inc.

The Companys offering provides the clinical interpretation of genetic variants present in human tum or biopsies, and is sold directly to diagnostic labs that perform molecular testing on patients. Its Genetic Variant Application (GVA) is compiled by its software platform to provide specific insights to a patients diagnostic test results on a test-by-test basis. The GVA results are provided to laboratories in a variety of forms, including with a front-end user Interface (UI) or directly integrated into a customers laboratory information management system (LIMS). The Companys content is identified as Powered by CollabRx within the test report. Portions of its Web-based applications are available free to physicians and patients through commercial on-line media partners under a license and advertising or sponsorship revenue sharing arrangement. The content that, the Company offers to laboratories is sold based on a variation of Software as a service (SaaS) business model, in which its content is provided on a one-time, subscription or per test basis. It also receives ! fee-for-service payments in connection with customized user ! interfaces to its database.

Advisors' Opinion:
  • [By Bryan Murphy]

    Enter CollabRx Inc. (NASDAQ:CLRX) - a provider of an overdue solution to the aforementioned problem.

    In simplest terms, CLRX has built a website designed to be used doctors - oncologists in particular - who need to stay up-to-date on all the latest treatment options for cancer patients. And it's not just a list of the most apropos drugs that might be well-suited for a particular type of cancer [the kind of detailed diagnosis that genetic testing now allows] that the CollabRx app offers. The website, available by subscription, also suggests clinical trials that may be worth a shot if the patient is so inclined... or if the normal treatment regimens aren't working.

  • [By Bryan Murphy]

    They say you're known by the caliber of company you keep. If that's true for stocks (and it is), then CollabRx Inc. (NASDAQ:CLRX) has a lot to be proud of with its new partnership with Affymetrix, Inc. (NASDAQ:AFFX). On the flipside, Affymetrix should be honored it's inked a deal with CollabRx. In a combination that hasn't been topped since peanut butter and chocolate hooked up to form a Reese's cup, AFFX and CLRX help bring out the best in each other.

  • [By Bryan Murphy]

    It's yet another case of technology converging with healthcare, though truth be told, the Bridgeline only scratches the surface of how the digital world and the patient-care world can unite to create something greater than the sum of its parts. A little company called CollabRx Inc. (NASDAQ:CLRX) is taking it up a notch - maybe two notches - to turn the web into a guidance portal for oncologists seeking new and better treatment options for cancer patients. Among these options are drug trials that a caregiver may not even be aware of, were it not for this highly-specialized site CLRX has designed.

  • source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-10-tech-companies-to-invest-in-2015-2.html

No comments:

Post a Comment